NasdaqGS:SRPTBiotechs
Sarepta Therapeutics (SRPT) Restructures After ELEVIDYS Setbacks and Regulatory Scrutiny Is the Investment Thesis Shifting
In recent weeks, Sarepta Therapeutics reported its second quarter 2025 results, disclosed a class action lawsuit related to ELEVIDYS safety concerns, and saw the European Medicines Agency recommend refusing marketing authorization for the gene therapy amid patient safety issues and regulatory scrutiny.
The company is undergoing significant restructuring, including workforce reductions and a black box warning on ELEVIDYS, while also filing a US$77.05 million shelf registration tied to...